GT Biopharma (NASDAQ:GTBP) Trading Down 2.6%

GT Biopharma, Inc. (NASDAQ:GTBP) shares traded down 2.6% during mid-day trading on Friday . The company traded as low as $4.15 and last traded at $4.25. 3,577 shares were traded during trading, a decline of 71% from the average session volume of 12,546 shares. The stock had previously closed at $4.36.

GT Biopharma Stock Performance

The stock has a market cap of $5.73 million, a P/E ratio of -0.46 and a beta of 0.59. The stock has a 50-day moving average price of $4.56 and a 200-day moving average price of $6.31.

Hedge Funds Weigh In On GT Biopharma

A number of large investors have recently bought and sold shares of GTBP. Atria Wealth Solutions Inc. bought a new stake in shares of GT Biopharma in the 1st quarter worth approximately $29,000. Renaissance Technologies LLC bought a new stake in shares of GT Biopharma in the 4th quarter worth approximately $41,000. Jane Street Group LLC boosted its position in shares of GT Biopharma by 64.8% during the fourth quarter. Jane Street Group LLC now owns 53,918 shares of the company’s stock valued at $48,000 after purchasing an additional 21,201 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of GT Biopharma by 18,317.6% during the fourth quarter. Wells Fargo & Company MN now owns 100,560 shares of the company’s stock valued at $89,000 after purchasing an additional 100,014 shares in the last quarter. Finally, FMR LLC boosted its position in shares of GT Biopharma by 7.6% during the second quarter. FMR LLC now owns 55,225 shares of the company’s stock valued at $165,000 after purchasing an additional 3,880 shares in the last quarter. 8.15% of the stock is owned by hedge funds and other institutional investors.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.